Quantcast

Latest GlaxoSmithKline Stories

2014-08-20 16:25:21

LONDON, Aug. 20, 2014 /PRNewswire/ -- GlaxoSmithKline plc today announced that the FDA has approved Arnuity(TM) Ellipta(®) (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. The approved doses are Arnuity Ellipta 100mcg and 200mcg. Arnuity Ellipta is administered once daily via the dry...

2014-08-18 23:03:09

MarketOptimizer.org adds “CountryFocus Healthcare, Regulatory and Reimbursement Landscape – Poland” to its store. The pharmaceutical market had decreased from $8.8 billion in 2011 to $7.1 billion in 2012. Dallas, Texas (PRWEB) August 18, 2014 Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in...

2014-08-18 23:02:04

Discover a new revolutionary product that is designed to nourish the brain. Minneapolis, MN (PRWEB) August 18, 2014 In celebration of the 100th anniversary of Dr. Forrest C. Shaklee beginning his pioneering work leading to the invention of Vitalized Minerals, one of the first multivitamin supplements in the world, and many other groundbreaking products, Shaklee Corporation is once again demonstrating its commitment to safe, scientifically validated products that help people live healthier...

2014-08-14 08:30:05

First Patient Dosed in the EU Post-Authorization Safety Study MOUNTAIN VIEW, Calif., Aug. 14, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its European Medicines Agency (EMA) post-approval studies for ADASUVE(®) inhalation powder, pre-dispensed (loxapine). As part of the ADASUVE approval process with the EMA, Alexza is required to conduct five post-approval studies: -- a benzodiazepine interaction study - study completed and data...

2014-08-05 08:35:30

New site is filled with information, patient testimonials, easy-to-use tools and real-world tips for people affected by COPD RESEARCH TRIANGLE PARK, N.C., Aug. 5, 2014 /PRNewswire/ -- Today GlaxoSmithKline plc (LSE/NYSE: GSK) announced the launch of the redesigned COPD.com website, which provides disease education, interactive tools, tips and inspirational testimonials from patients living with chronic obstructive pulmonary disease (COPD), for an up-close and personal look at managing and...

2014-07-27 12:20:59

LifeScienceIndustryResearch.com adds Latest Report on "Global and Chinese Vardenafil (CAS 224785-90-4) Industry, 2009-2019 Market Research Report" to its store. DALLAS, July 27, 2014 /PRNewswire-iReach/ -- This is a professional and in-depth market survey on Global and Chinese Vardenafil (CAS 224785-90-4) industry. The report firstly reviews the basic information of Vardenafil (CAS 224785-90-4) including its classification, application and manufacturing technology. The report then...

2014-07-25 08:25:20

DUBLIN, July 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Nicotine Gum Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Nicotine gum is a smoking cessation product that helps smokers to slowly overcome nicotine addiction. Nicotine is released by chewing the gum and is absorbed into the blood stream through the lining of the mouth, which helps smokers to slowly reduce their craving for nicotine. Nicotine...

2014-07-24 16:26:21

No. 1 Prescribed Allergy Treatment Ingredient(1) to be Available OTC PARSIPPANY, N.J., July 24, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray), containing the No. 1 prescribed allergy treatment ingredient(1), as an over-the-counter (OTC) treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies.(2) Flonase®...

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-07-23 08:30:55

LONDON, July 23, 2014 /PRNewswire/ -- Global healthcare company GSK reports Q2 results reflecting a business that is facing currency headwinds, increased price competition and supply disruptions to its Consumer business. However its CEO Sir Andrew Witty points out that the company is very much in transition, citing progress in the development pipeline as reason to be confident about long-term prospects as well as the investments being made to drive long-term growth. CFO...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.